Last reviewed · How we verify
NCT06159686
The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
Phase 1, PHASE2 trial testing Hemp in Uremic Pruritus in 60 participants. Completed in 8 December 2023.
8 December 2023
Quick facts
| Lead sponsor | Thammasat University Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 15 September 2023 |
| Primary completion | 8 December 2023 |
| Estimated completion | 8 December 2023 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Hemp — full drug profile →
- Placebo
Conditions studied
- Uremic Pruritus — all drugs for Uremic Pruritus →
Sponsor
Thammasat University Hospital
Who can join
18 and older, any sex, with Uremic Pruritus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Uremic pruritus is a significant burden on hemodialysis patients, affecting approximately 46% of individuals undergoing dialysis. Various mechanisms, including inadequate dialysis, increased uremic toxins, inflammatory cytokines, parathyroid hormone, phosphorus, dry skin, mast cell histamine secretion, and nerve stimulation through μ-opioid receptors and nociceptors, contribute to uremic pruritus. Current treatments include antihistamines, gabapentin, moisturizer creams, and capsaicin creams, with limited success, as only 10% of patients find relief. Cannabinoids were also mentioned in uremic pruritus treatment but are less commonly used and there are no randomised controlled trial. Cannabinoid binding to CB1 and CB2 receptors inhibits mast cell differentiation, aggregation, and histamine release, whereas cannabinoid binding to TRP-iron receptors reduces peripheral nerve activation. Thus, cannabinoid seem to effective in relieving pruritus via various mechanisms. This study aims to assess the effectiveness of a hemp-containing cream in comparison to a placebo for treating uremic pruritus among hemodialysis patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cannabis-Containing Cream for CKD-Associated Pruritus: A Double-Blind, Placebo Controlled Trial.
Anumas S, Kuropakornpong P, Chakkavittumrong P, Tasanarong A, et al · · 2024 · cited 4× · PMID 39328960 · DOI 10.1016/j.xkme.2024.100894
Verify or expand the search:
- PubMed search for NCT06159686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uremic Pruritus
Currently open trials in the same condition.
- NCT06446310 — Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus · Phase 3 · recruiting
Other Thammasat University Hospital trials
Trials by the same sponsor.
- NCT06910930 — Impact of Muscle Training Device on Non-Severe OSA · NA · recruiting
- NCT06943053 — Evaluation of Ioband Coverage Waterproof Dressing Versus Isolated Waterproof Dressing After Primary Total Knee Arthropla · NA · recruiting
- NCT06800846 — Comparative Analgesic Effect After Total Knee Arthroplasty Between Intraosseous and Peri-articular Injection · Phase 4 · enrolling by invitation
- NCT06328062 — Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA · NA · recruiting
- NCT06323577 — Comparing Efficacy Between Restricted Kinematic Alignment vs Mechanical Alignment in Bilateral TKA · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06159686 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Thammasat University Hospital
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06159686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing